Partners will develop targeted miRNAs to treat pancreatic cancer
Drug Discovery World
MARCH 3, 2023
SiSaf will develop miRNA Bio-Courier formulations that will be tested in pancreatic cancer models in Professor Aigner’s laboratory. Under the terms of the agreement SiSaf has an exclusive option to acquire a worldwide license to a patent by the University.
Let's personalize your content